Els Lierman

Leuven, VLG, Belgium

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.

The chromosomal translocation t(1;6)(p35.3;p25.2), recurrent in chronic lymphocytic leukaemia, leads to RCC1::IRF4 fusion.

Journal: British journal of haematology

Published: July 24, 2024

t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia.

t(9;12)(q22;p13) ETV6::SYK: A new recurrent cytogenetic aberration and tyrosine kinase gene fusion in myeloid or lymphoid neoplasms associated with eosinophilia.

Journal: British journal of haematology

Published: June 20, 2022

Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms.

Next generation sequencing in therapy-related myeloid neoplasms compared to de novo myeloid neoplasms.

Journal: Acta clinica Belgica

Published: July 01, 2021

Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.

Standardization of Somatic Variant Classifications in Solid and Haematological Tumours by a Two-Level Approach of Biological and Clinical Classes: An Initiative of the Belgian ComPerMed Expert Panel.

Journal: Cancers

Published: November 13, 2019

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia.

FIP1L1-PDGFRα p.T674I-D842L: A Novel and Ponatinib Resistant Compound Mutation in FIP1L1-PDGFRα Positive Leukemia.

Journal: HemaSphere

Published: November 20, 2018

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

Coexisting driver mutations in MPN: clinical and molecular characteristics of a series of 11 patients.

Journal: Hematology (Amsterdam, Netherlands)

Published: July 12, 2018

A monocentric retrospective study of 138 therapy-related myeloid neoplasms.

A monocentric retrospective study of 138 therapy-related myeloid neoplasms.

Journal: Annals of hematology

Published: May 23, 2018

Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.

Highly sensitive assays are mandatory for the differential diagnosis of patients presenting with symptoms of mast cell activation: diagnostic work-up of 38 patients.

Journal: Acta clinica Belgica

Published: March 07, 2017

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Efficacy of ruxolitinib in myeloid neoplasms with PCM1-JAK2 fusion gene.

Journal: Annals of hematology

Published: March 26, 2015

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Analysis of phenotype and outcome in essential thrombocythemia with CALR or JAK2 mutations.

Journal: Haematologica

Published: October 01, 2014

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.

Screening of JAK2 V617F and MPL W515 K/L negative essential thrombocythaemia patients for mutations in SESN2, DNAJC17, ST13, TOP1MT, and NTRK1.

Journal: British journal of haematology

Published: March 12, 2014

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Identification of Ponatinib as a potent inhibitor of growth, migration, and activation of neoplastic eosinophils carrying FIP1L1-PDGFRA.

Journal: Experimental hematology

Published: May 15, 2013

Showing 1-12 of 14

Last Updated: 09/26/2026